LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

United Therapeutics Corp

Închisă

SectorSănătate

325.71 1.95

Rezumat

Modificarea prețului

24h

Curent

Minim

318.22

Maxim

325.89

Indicatori cheie

By Trading Economics

Venit

21M

322M

Vânzări

59M

794M

P/E

Medie Sector

12.988

51.198

EPS

6.63

Marjă de profit

40.559

Angajați

1,305

EBITDA

-41M

383M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+15.34% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.6B

15B

Deschiderea anterioară

323.76

Închiderea anterioară

325.71

Sentimentul știrilor

By Acuity

50%

50%

166 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

United Therapeutics Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 oct. 2024, 15:14 UTC

Principalele dinamici ale pieței

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparație

Modificare preț

United Therapeutics Corp Așteptări

Obiectiv de preț

By TipRanks

15.34% sus

Prognoză pe 12 luni

Medie 375.8 USD  15.34%

Maxim 432 USD

Minim 314 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUnited Therapeutics Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

7

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

292.345 / 309.245Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

166 / 380 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.